Cargando…
Antibody-CD20-interferon-alpha fusion protein has superior in vivo activity against human B cell lymphomas compared to Rituximab, and enhanced complement-dependent cytotoxicity in vitro
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991073/ http://dx.doi.org/10.1186/2051-1426-1-S1-P263 |
| _version_ | 1782312377196216320 |
|---|---|
| author | Yamada, Reiko Steward, Kristopher Ngarmchamnanrith, Gataree Trinh, Ryan Khare, Sanjay Sachdev, Raj Grewal, Iqbal Morrison, Sherie Timmerman, John |
| author_facet | Yamada, Reiko Steward, Kristopher Ngarmchamnanrith, Gataree Trinh, Ryan Khare, Sanjay Sachdev, Raj Grewal, Iqbal Morrison, Sherie Timmerman, John |
| author_sort | Yamada, Reiko |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-3991073 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2013 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-39910732014-05-01 Antibody-CD20-interferon-alpha fusion protein has superior in vivo activity against human B cell lymphomas compared to Rituximab, and enhanced complement-dependent cytotoxicity in vitro Yamada, Reiko Steward, Kristopher Ngarmchamnanrith, Gataree Trinh, Ryan Khare, Sanjay Sachdev, Raj Grewal, Iqbal Morrison, Sherie Timmerman, John J Immunother Cancer Poster Presentation BioMed Central 2013-11-07 /pmc/articles/PMC3991073/ http://dx.doi.org/10.1186/2051-1426-1-S1-P263 Text en Copyright © 2013 Yamada et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Poster Presentation Yamada, Reiko Steward, Kristopher Ngarmchamnanrith, Gataree Trinh, Ryan Khare, Sanjay Sachdev, Raj Grewal, Iqbal Morrison, Sherie Timmerman, John Antibody-CD20-interferon-alpha fusion protein has superior in vivo activity against human B cell lymphomas compared to Rituximab, and enhanced complement-dependent cytotoxicity in vitro |
| title | Antibody-CD20-interferon-alpha fusion protein has superior in vivo activity against human B cell lymphomas compared to Rituximab, and enhanced complement-dependent cytotoxicity in vitro |
| title_full | Antibody-CD20-interferon-alpha fusion protein has superior in vivo activity against human B cell lymphomas compared to Rituximab, and enhanced complement-dependent cytotoxicity in vitro |
| title_fullStr | Antibody-CD20-interferon-alpha fusion protein has superior in vivo activity against human B cell lymphomas compared to Rituximab, and enhanced complement-dependent cytotoxicity in vitro |
| title_full_unstemmed | Antibody-CD20-interferon-alpha fusion protein has superior in vivo activity against human B cell lymphomas compared to Rituximab, and enhanced complement-dependent cytotoxicity in vitro |
| title_short | Antibody-CD20-interferon-alpha fusion protein has superior in vivo activity against human B cell lymphomas compared to Rituximab, and enhanced complement-dependent cytotoxicity in vitro |
| title_sort | antibody-cd20-interferon-alpha fusion protein has superior in vivo activity against human b cell lymphomas compared to rituximab, and enhanced complement-dependent cytotoxicity in vitro |
| topic | Poster Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991073/ http://dx.doi.org/10.1186/2051-1426-1-S1-P263 |
| work_keys_str_mv | AT yamadareiko antibodycd20interferonalphafusionproteinhassuperiorinvivoactivityagainsthumanbcelllymphomascomparedtorituximabandenhancedcomplementdependentcytotoxicityinvitro AT stewardkristopher antibodycd20interferonalphafusionproteinhassuperiorinvivoactivityagainsthumanbcelllymphomascomparedtorituximabandenhancedcomplementdependentcytotoxicityinvitro AT ngarmchamnanrithgataree antibodycd20interferonalphafusionproteinhassuperiorinvivoactivityagainsthumanbcelllymphomascomparedtorituximabandenhancedcomplementdependentcytotoxicityinvitro AT trinhryan antibodycd20interferonalphafusionproteinhassuperiorinvivoactivityagainsthumanbcelllymphomascomparedtorituximabandenhancedcomplementdependentcytotoxicityinvitro AT kharesanjay antibodycd20interferonalphafusionproteinhassuperiorinvivoactivityagainsthumanbcelllymphomascomparedtorituximabandenhancedcomplementdependentcytotoxicityinvitro AT sachdevraj antibodycd20interferonalphafusionproteinhassuperiorinvivoactivityagainsthumanbcelllymphomascomparedtorituximabandenhancedcomplementdependentcytotoxicityinvitro AT grewaliqbal antibodycd20interferonalphafusionproteinhassuperiorinvivoactivityagainsthumanbcelllymphomascomparedtorituximabandenhancedcomplementdependentcytotoxicityinvitro AT morrisonsherie antibodycd20interferonalphafusionproteinhassuperiorinvivoactivityagainsthumanbcelllymphomascomparedtorituximabandenhancedcomplementdependentcytotoxicityinvitro AT timmermanjohn antibodycd20interferonalphafusionproteinhassuperiorinvivoactivityagainsthumanbcelllymphomascomparedtorituximabandenhancedcomplementdependentcytotoxicityinvitro |